Eli Lilly Posts Strong Growth on Mounjaro and GLP-1 Demand; Barclays Maintains Positive Outlook

The news highlights strong demand for Eli Lilly's flagship products Mounjaro and GLP-1 drugs, with Barclays maintaining a positive outlook providing support for the stock. Technically, the stock has risen 4.9% in the last 24 hours, and the RSI at 66.7 has not yet approached overbought territory, suggesting that upward momentum could continue in the short term. The MACD line is above the signal line and in positive territory, confirming the uptrend. The price is trading above the 20-day and 50-day moving averages, reinforcing the short-term outlook. However, caution is warranted as the RSI approaches the 70 level and a short-term correction is possible following the recent rally.

Eli Lilly's strong growth news indicates that rising demand, particularly for GLP-1 drugs, is creating positive momentum in the healthcare sector. This could increase optimism for pharmaceutical and biotechnology stocks in global markets. In Turkish markets, a short-term positive impact may be expected on healthcare sector stocks and pharmaceutical distribution companies. However, this effect is likely to be limited as the news is not directly related to Turkey-specific developments.